Press Releases

Tigermed Completes Acquisition of CRO Medical Edge

Jul 26, 2024

Hangzhou, China, and Tokyo, Japan, July 26, 2024 — Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of CRO company Medical Edge.


Founded in 2015 and headquartered in Tokyo, Medical Edge is a contract research organization (CRO) specializing in data management, biostatistics, electronic data capture systems (EDC), and customized ePRO system services. Through its professional R&D services, rigorous scientific approach, and efficient operational management, Medical Edge has earned the trust of many pharmaceutical and biotechnology companies, establishing a strong reputation in Japan’s clinical research industry.


Following the acquisition, Medical Edge will become a wholly-owned subsidiary of Tigermed Japan, providing high-quality data statistics and electronic data solutions for clinical research in Japan. Additionally, through Medical Edge's customer base and brand influence in the Japanese and Asian markets, Tigermed aims to integrate technological advantages and talent resources, further expanding its R&D service capabilities and business scale in the Asia-Pacific region.


“It is a great honor to join Tigermed!” said Mr. Shiro Ueda, founder and CEO of Medical Edge. “Medical Edge has been deeply engaged in the Japanese medical market for many years, accumulating extensive experience in clinical development. We believe this valuable experience will strongly support Tigermed in the clinical data services field. Meanwhile, Tigermed’s global business network and resources will offer us a broader platform for development.”


“Medical Edge’s rich experience and outstanding performance in the Japanese market align closely with Tigermed’s global vision,” said Mr. Hao Wu, Co-President of Tigermed. “We will fully leverage Medical Edge’s local advantages to build a more efficient clinical research data management system, provide customers with one-stop clinical research services, and enhance Tigermed’s global competitiveness.”


About Medical Edge Co., Ltd

Medical Edge Co., Ltd, founded in 2015 and headquartered in Tokyo, Japan, is a contract research organization (CRO) specializing in EDC development, customized system solutions, data analysis, and biostatistics. The company is committed to advancing the healthcare field by addressing challenges through systematic approaches, with main services including data management, biostatistics, EDC, and ePRO system customization.


About Tigermed

Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,000 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.


For more information:

Investors: ir@tigermedgrp.com

Media: pr@tigermedgrp.com